These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2880242)

  • 21. Is the Detection of Factor IX Inhibitors in Hemophilia B Orphan than Factor VIII Inhibitors in Hemophilia A? A Concise, Systematic Review.
    Mansouritorghabeh H; Mohades ST
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(3):185-190. PubMed ID: 32611303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hemophiliacs with inhibitor. Experience at the Center of Medical Action for Hemophilia of the S. José Hospital].
    Diniz MJ; Dias Francisco F; Tavares ML; Leal I
    Acta Med Port; 1992 Apr; 5(4):178-80. PubMed ID: 1605065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive care for haemophilia.
    Kerr CB
    J R Coll Physicians Lond; 1971 Apr; 5(3):263-7. PubMed ID: 5163724
    [No Abstract]   [Full Text] [Related]  

  • 24. [Study of the "in vivo" activity of factor VIII or factor IX after injection of several concentrates: practical applications].
    Allain JP
    Nouv Rev Fr Hematol; 1972; 12(2):241-9. PubMed ID: 4264617
    [No Abstract]   [Full Text] [Related]  

  • 25. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
    Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orthotopic liver transplantation in a patient with combined hemophilia A and B.
    Delorme MA; Adams PC; Grant D; Ghent CN; Walker IR; Wall WJ
    Am J Hematol; 1990 Feb; 33(2):136-8. PubMed ID: 2105634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
    Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
    Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro characterization of various heat-treated prothrombin complex concentrates (PCC).
    Yoshioka A; Nakagawa O; Uehara Y; Sakai T; Sugimoto M; Takamiya O; Tanaka I; Fukui H
    Thromb Res; 1987 Aug; 47(4):449-58. PubMed ID: 2958958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hemophilia.
    Buchanan GR
    Pediatr Clin North Am; 1980 May; 27(2):309-26. PubMed ID: 6770324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A; Kuwashima M; Nagao T
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract]   [Full Text] [Related]  

  • 35. ["Inhibitory" form of hemophilia in children].
    Mazurin AV; Iakunina LN; Plakhuta TG
    Probl Gematol Pereliv Krovi; 1978 Jul; (7):18-21. PubMed ID: 674137
    [No Abstract]   [Full Text] [Related]  

  • 36. A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B.
    Keeling D; Beavis J; Sukhu K
    Br J Haematol; 2005 Mar; 128(6):885. PubMed ID: 15755295
    [No Abstract]   [Full Text] [Related]  

  • 37. The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
    Engelfriet CP; Reesink HW; Mannucci PM; Gringeri A; Ingerslev J; Brettler DB; Mauser-Bunschoten EP; Negrier C; Berntorp E; Smith OP; Shapiro AD
    Vox Sang; 2000; 78(4):256-61. PubMed ID: 10970234
    [No Abstract]   [Full Text] [Related]  

  • 38. Substitution treatment of hemophilia a and b.
    Duckert F
    Schweiz Med Wochenschr; 1975 Jun; 105(24):783-4. PubMed ID: 1145162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia.
    Greer IA; Greaves M; Madhok R; McLoughlin K; Porter N; Lowe GD; Preston FE; Forbes CD
    Thromb Haemost; 1985 Jun; 53(3):386-9. PubMed ID: 3931287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.